Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 89
Filtrar
2.
J Int AIDS Soc ; 15(2): 17428, 2012 Jun 14.
Artigo em Inglês | MEDLINE | ID: mdl-22713261

RESUMO

BACKGROUND: Tuberculosis (TB) continues to be the most frequent cause of illness and death from an infectious agent globally, and its interaction with HIV is having devastating effects. To investigate how HIV alters the immune response to Mycobacterium tuberculosis (Mtb), we assessed basal and Mtb-induced proliferation, cytokine production, and expression of signalling lymphocytic activation molecule (SLAM), inducible costimulator (ICOS) and programmed death-1 (PD-1) on T lymphocytes from HIV-positive individuals coinfected with TB, HIV-positive subjects, TB patients and healthy donors (HD). FINDINGS: HIV-TB patients showed increased ICOS, SLAM and PD-1 basal levels on T lymphocytes, whereas HIV-positive individuals displayed elevated levels of SLAM and PD-1, TB patients high levels of SLAM, and HD low levels of the three proteins. Mtb-stimulation enhanced ICOS expression in the four groups, but only TB and HD increased SLAM and PD-1 levels. CONCLUSIONS: These data show the immune deregulation that takes place during the immune response against TB in different study populations.


Assuntos
Antígenos CD/biossíntese , Perfilação da Expressão Gênica , Infecções por HIV/complicações , Proteína Coestimuladora de Linfócitos T Induzíveis/biossíntese , Receptor de Morte Celular Programada 1/biossíntese , Receptores de Superfície Celular/biossíntese , Linfócitos T/imunologia , Tuberculose Pulmonar/imunologia , Proliferação de Células , Citocinas/metabolismo , Humanos , Membro 1 da Família de Moléculas de Sinalização da Ativação Linfocitária , Linfócitos T/química
3.
PLoS One ; 7(2): e32275, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22384203

RESUMO

The monocyte chemotactic protein-1 (MCP-1) is a chemokine that plays an important role in the recruitment of monocytes to M. tuberculosis infection sites, and previous studies have reported that genetic variants in MCP1 are associated with differential susceptibility to pulmonary tuberculosis (PTB). We examined eight MCP1 single nucleotide polymorphisms (SNPs) in a multi-ethnic, case-control design that included: 321 cases and 346 controls from Guinea-Bissau, 258 cases and 271 controls from The Gambia, 295 cases and 179 controls from the U.S. (African-Americans), and an additional set of 237 cases and 144 controls of European ancestry from the U.S. and Argentina. Two locus interactions were also examined for polymorphisms in MCP1 and interleukin 12B (IL12B), another gene implicated in PTB risk. Examination of previously associated MCP1 SNPs rs1024611 (-2581A/G), rs2857656 (-362G/C) and rs4586 (+900C/T) did not show evidence for association. One interaction between rs2857656 and IL12B SNP rs2288831 was observed among Africans but the effect was in the opposite direction in Guineans (OR = 1.90, p = 0.001) and Gambians (OR = 0.64, p = 0.024). Our data indicate that the effect of genetic variation within MCP1 is not clear cut and additional studies will be needed to elucidate its role in TB susceptibility.


Assuntos
Quimiocina CCL2/genética , Epistasia Genética , Subunidade p40 da Interleucina-12/genética , Polimorfismo Genético , Tuberculose Pulmonar/diagnóstico , Tuberculose Pulmonar/genética , Adolescente , Adulto , Negro ou Afro-Americano , Idoso , Argentina , População Negra , Estudos de Casos e Controles , Quimiocina CCL2/biossíntese , Etnicidade , Feminino , Gâmbia , Predisposição Genética para Doença , Variação Genética , Guiné-Bissau , Humanos , Masculino , Pessoa de Meia-Idade , Estados Unidos , População Branca
4.
J Antimicrob Chemother ; 67(2): 473-7, 2012 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-22134348

RESUMO

OBJECTIVES: Current drug choices to treat extensively drug-resistant (XDR) tuberculosis (TB) are scarce; therefore, information on the safety, tolerability and efficacy of alternative regimens is of utmost importance. The aim of this study was to describe the management, drug adverse effects and outcome of alternative combined treatment in a series of XDR-TB patients. PATIENTS AND METHODS: A retrospective study was performed on 17 non-AIDS, pulmonary adult patients with XDR-TB admitted to a referral treatment centre for infectious diseases in Buenos Aires from 2002 through 2008. Drug susceptibility testing was performed under regular proficiency testing and confirmed at the national TB reference laboratory. RESULTS: Linezolid was included in the drug regimens of all patients; moxifloxacin and/or thioridazine were included in the regimens of 14 patients. Clinically tractable drug adverse effects were observed in nine patients, the most frequent being haematological disorders and neurotoxicity. In two patients, thioridazine was discontinued. Negative culture conversion was achieved in 15 patients, 11 completed treatment meeting cure criteria, 4 are still on follow-up with good evolution, 1 defaulted treatment and 1 was lost to follow-up. CONCLUSIONS: The combination of linezolid, moxifloxacin and thioridazine is recommended for compassionate use in specialized centres with expertise in the management of XDR-TB.


Assuntos
Acetamidas/administração & dosagem , Antituberculosos/administração & dosagem , Compostos Aza/administração & dosagem , Tuberculose Extensivamente Resistente a Medicamentos/tratamento farmacológico , Oxazolidinonas/administração & dosagem , Quinolinas/administração & dosagem , Tioridazina/administração & dosagem , Acetamidas/efeitos adversos , Adulto , Antituberculosos/efeitos adversos , Argentina , Compostos Aza/efeitos adversos , Ensaios de Uso Compassivo/métodos , Farmacorresistência Bacteriana Múltipla , Tuberculose Extensivamente Resistente a Medicamentos/microbiologia , Feminino , Fluoroquinolonas , Humanos , Linezolida , Masculino , Pessoa de Meia-Idade , Moxifloxacina , Mycobacterium tuberculosis/efeitos dos fármacos , Mycobacterium tuberculosis/isolamento & purificação , Oxazolidinonas/efeitos adversos , Quinolinas/efeitos adversos , Estudos Retrospectivos , Tioridazina/efeitos adversos , Resultado do Tratamento , Tuberculose Pulmonar/tratamento farmacológico , Tuberculose Pulmonar/microbiologia
5.
J Infect Dis ; 204(7): 1054-64, 2011 Oct 01.
Artigo em Inglês | MEDLINE | ID: mdl-21881121

RESUMO

BACKGROUND: The proinflammatory cytokine interleukin 17 (IL-17) plays an important role in immune responses but it is also associated with tissue-damaging inflammation. So, we evaluated the ability of Mycobacterium tuberculosis clinical isolates to induce IL-17 in tuberculosis (TB) patients and in healthy human tuberculin reactors (PPD(+)HD). METHODS: IL-17, interferon γ (IFN-γ), and interleukin 23 (IL-23) receptor expression were evaluated ex vivo and cultured peripheral blood mononuclear cells from TB and PPD(+)HD stimulated with irradiated clinical isolates from multidrug resistant (MDR) outbreaks M (Haarlem family) and Ra (Latin American-Mediterranean family), as well as drug-susceptible isolates belonging to the same families and laboratory strain H37Rv for 48 hours in T-cell subsets by flow cytometry. RESULTS: We observed that: (1) MDR strains M and Ra are stronger IL-17 inducers than drug-susceptible Mtb strains of the Haarlem and Latin American-Mediterranean families, (2) MDR-TB patients show the highest IL-17 expression that is independent on the strain, (3) IL-17 expression is dependent on CD4(+) and CD8(+) T cells associates with persistently high antigen load. CONCLUSIONS: IL-17--producing T cells could play an immunopathological role in MDR-TB promoting severe tissue damage, which may be associated with the low effectiveness of the second-line drugs employed in the treatment.


Assuntos
Antígenos de Bactérias/imunologia , Linfócitos T CD4-Positivos/metabolismo , Linfócitos T CD8-Positivos/metabolismo , Mycobacterium tuberculosis/imunologia , Subpopulações de Linfócitos T/imunologia , Tuberculose Resistente a Múltiplos Medicamentos/imunologia , Adulto , Células Cultivadas , Feminino , Humanos , Interferon gama/metabolismo , Interleucina-17/metabolismo , Masculino , Pessoa de Meia-Idade , Receptores de Antígenos de Linfócitos T gama-delta/imunologia , Receptores de Antígenos de Linfócitos T gama-delta/metabolismo , Receptores de Interleucina/metabolismo , Subpopulações de Linfócitos T/metabolismo , Adulto Jovem
6.
J Leukoc Biol ; 90(1): 69-75, 2011 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-21454357

RESUMO

The role of CD16(-) and CD16(+) Mo subsets in human TB remains unknown. Our aim was to characterize Mo subsets from TB patients and to assess whether the inflammatory milieu from TB pleurisy modulate their phenotype and recruitment. We found an expansion of peripheral CD16(+) Mo that correlated with disease severity and with TNF-α plasma levels. Circulating Mo from TB patients are activated, showing a higher CD14, CD16, and CD11b expression and Mtb binding than HS. Both subsets coexpressed CCR2/CCR5, showing a potential ability to migrate to the inflammatory site. In tuberculous PF, the CD16(+) subset was the main Mo/MΦ population, accumulation that can be favored by the induction of CD16 expression in CD16(-) Mo triggered by soluble factors found in this inflammatory milieu. CD16(+) Mo in PF were characterized by a high density of receptors for Mtb recognition (DC-SIGN, MR, CD11b) and for lipid-antigens presentation (CD1b), allowing them to induce a successful, specific T cell proliferation response. Hence, in tuberculous PF, CD16(+) Mo constitute the main APC population; whereas in PB, their predominance is associated with the severity of pulmonary TB, suggesting a paradoxical role of the CD16(+) Mo subset that depends on the cellular localization.


Assuntos
Monócitos/imunologia , Receptores CCR2/análise , Receptores CCR5/análise , Receptores de IgG/análise , Tuberculose Pleural/imunologia , Tuberculose/imunologia , Adulto , Idoso , Células Apresentadoras de Antígenos/imunologia , Células Apresentadoras de Antígenos/metabolismo , Separação Celular , Citocinas/análise , Citocinas/sangue , Ensaio de Imunoadsorção Enzimática , Feminino , Citometria de Fluxo , Proteínas Ligadas por GPI/análise , Proteínas Ligadas por GPI/imunologia , Proteínas Ligadas por GPI/metabolismo , Humanos , Masculino , Pessoa de Meia-Idade , Monócitos/metabolismo , Derrame Pleural/imunologia , Derrame Pleural/metabolismo , Receptores CCR2/imunologia , Receptores CCR2/metabolismo , Receptores CCR5/imunologia , Receptores CCR5/metabolismo , Receptores de IgG/imunologia , Receptores de IgG/metabolismo , Tuberculose/metabolismo , Tuberculose Pleural/metabolismo
7.
PLoS One ; 6(2): e16656, 2011 Feb 09.
Artigo em Inglês | MEDLINE | ID: mdl-21339808

RESUMO

We examined whether polymorphisms in interleukin-12B (IL12B) associate with susceptibility to pulmonary tuberculosis (PTB) in two West African populations (from The Gambia and Guinea-Bissau) and in two independent populations from North and South America. Nine polymorphisms (seven SNPs, one insertion/deletion, one microsatellite) were analyzed in 321 PTB cases and 346 controls from Guinea-Bissau and 280 PTB cases and 286 controls from The Gambia. For replication we studied 281 case and 179 control African-American samples and 221 cases and 144 controls of European ancestry from the US and Argentina. First-stage single locus analyses revealed signals of association at IL12B 3' UTR SNP rs3212227 (unadjusted allelic p = 0.04; additive genotypic p = 0.05, OR = 0.78, 95% CI [0.61-0.99]) in Guinea-Bissau and rs11574790 (unadjusted allelic p = 0.05; additive genotypic p = 0.05, OR = 0.76, 95% CI [0.58-1.00]) in The Gambia. Association of rs3212227 was then replicated in African-Americans (rs3212227 allelic p = 0.002; additive genotypic p = 0.05, OR = 0.78, 95% CI [0.61-1.00]); most importantly, in the African-American cohort, multiple significant signals of association (seven of the nine polymorphisms tested) were detected throughout the gene. These data suggest that genetic variation in IL12B, a highly relevant candidate gene, is a risk factor for PTB in populations of African ancestry, although further studies will be required to confirm this association and identify the precise mechanism underlying it.


Assuntos
Variação Genética , Subunidade p40 da Interleucina-12/genética , Tuberculose Pulmonar/genética , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Argentina/epidemiologia , População Negra/genética , Estudos de Casos e Controles , Estudos de Coortes , Feminino , Gâmbia/epidemiologia , Frequência do Gene , Estudos de Associação Genética , Variação Genética/fisiologia , Genética Populacional , Guiné-Bissau/epidemiologia , Humanos , Desequilíbrio de Ligação , Masculino , Pessoa de Meia-Idade , Polimorfismo de Nucleotídeo Único/fisiologia , Tuberculose Pulmonar/epidemiologia , Tuberculose Pulmonar/etnologia , Estados Unidos/epidemiologia , Adulto Jovem
9.
Salud(i)ciencia (Impresa) ; 17(8): 778-782, sept. 2010.
Artigo em Espanhol | LILACS | ID: lil-567636

RESUMO

La tuberculosis extensamente resistente a múltiples drogas (XDR-TB), resistente a isoniacida, rifampicina, alguna fluoroquinolona y al menos una entre kanamicina, amikacina, o capreomicina; ha sido descripta en la mayoría de las regiones del mundo con efectos devastadores. Por esta razón, la información sobre seguridad, tolerabilidad y eficacia acerca de drogas potencialmente útiles en su tratamiento es de extrema utilidad, no sólo para mejorar el pronóstico individual de estos pacientes sino también para controlar su diseminación. Se presentan 18 casos de localización pulmonar en pacientes sin Sida. Se trataron con esquemas que incluyeron en todos los casos linezolida; en 13, moxifloxacina, y en 13, tioridazina, todos negativizaron al examen directo y cultivo del esputo. Once pacientes cumplieron criterios de curación, 6 están aún en tratamiento y 3 abandonaron. Diez pacientes presentaron efectos adversos, en sólo 1 caso debió suspenderse la tioridazina. La utilización de linezolid, moxifloxacina y tioridazina ha contribuído a la evolución satisfactoria de estos pacientes. Estos fármacos son considerados de utilidad en esta serie, pero deben ser empleados en centros especializados con experiencia en el manejo de la XDR-TB.


Assuntos
Humanos , Masculino , Feminino , Usos Terapêuticos , Argentina , Mycobacterium tuberculosis , Tuberculose Resistente a Múltiplos Medicamentos/epidemiologia , Tuberculose Resistente a Múltiplos Medicamentos/tratamento farmacológico , Tuberculose Resistente a Múltiplos Medicamentos/terapia
10.
Salud(i)cienc., (Impresa) ; 17(8): 778-782, sept. 2010.
Artigo em Espanhol | BINACIS | ID: bin-125570

RESUMO

La tuberculosis extensamente resistente a múltiples drogas (XDR-TB), resistente a isoniacida, rifampicina, alguna fluoroquinolona y al menos una entre kanamicina, amikacina, o capreomicina; ha sido descripta en la mayoría de las regiones del mundo con efectos devastadores. Por esta razón, la información sobre seguridad, tolerabilidad y eficacia acerca de drogas potencialmente útiles en su tratamiento es de extrema utilidad, no sólo para mejorar el pronóstico individual de estos pacientes sino también para controlar su diseminación. Se presentan 18 casos de localización pulmonar en pacientes sin Sida. Se trataron con esquemas que incluyeron en todos los casos linezolida; en 13, moxifloxacina, y en 13, tioridazina, todos negativizaron al examen directo y cultivo del esputo. Once pacientes cumplieron criterios de curación, 6 están aún en tratamiento y 3 abandonaron. Diez pacientes presentaron efectos adversos, en sólo 1 caso debió suspenderse la tioridazina. La utilización de linezolid, moxifloxacina y tioridazina ha contribuído a la evolución satisfactoria de estos pacientes. Estos fármacos son considerados de utilidad en esta serie, pero deben ser empleados en centros especializados con experiencia en el manejo de la XDR-TB.(AU)


Assuntos
Humanos , Masculino , Feminino , Tuberculose Resistente a Múltiplos Medicamentos/terapia , Tuberculose Resistente a Múltiplos Medicamentos/epidemiologia , Tuberculose Resistente a Múltiplos Medicamentos/tratamento farmacológico , Mycobacterium tuberculosis , Usos Terapêuticos , Argentina
11.
J Infect Dis ; 202(4): 524-32, 2010 Aug 15.
Artigo em Inglês | MEDLINE | ID: mdl-20617899

RESUMO

Tuberculous pleurisy allows the study of specific cells at the site of Mycobacterium tuberculosis infection. Among pleural lymphocytes, natural killer (NK) cells are a major source of interferon gamma (IFN-gamma), and their functions are regulated by activating and inhibitory receptors. Programmed death-1 (PD-1), programmed death ligand 1 (PD-L1), and programmed death ligand 2 (PD-L2) are recognized inhibitory receptors in adaptive immunity, but their role during innate immunity remains poorly understood. We investigated the PD-1:PD-L1/PD-L2 pathway on NK cell effector functions in peripheral blood and pleural fluid from patients with tuberculosis. M. tuberculosis stimulation significantly up-regulated PD-1, PD-L1, and PD-L2 levels on NK cells. Interestingly, a direct correlation between PD-1 and IFN-gamma expression on NK cells was observed. Moreover, blockade of the PD-1 pathway markedly augmented lytic degranulation and IFN-gamma production of NK cells against M. tuberculosis. Furthermore, PD-1(+) NK cells displayed a diminished IFN-gamma mean fluorescence intensity, denoting the relevance of PD-1 on IFN-gamma regulation. Together, we described a novel inhibitory role played by PD-1:PD-L interactions in innate immunity in tuberculosis.


Assuntos
Antígenos CD/imunologia , Proteínas Reguladoras de Apoptose/imunologia , Apoptose , Imunidade Inata , Mycobacterium tuberculosis/imunologia , Tuberculose/imunologia , Tuberculose/patologia , Adulto , Antígeno B7-H1 , Sangue/imunologia , Perfilação da Expressão Gênica , Humanos , Peptídeos e Proteínas de Sinalização Intercelular/imunologia , Interferon gama/antagonistas & inibidores , Interferon gama/metabolismo , Células Matadoras Naturais/imunologia , Pleura/imunologia , Proteína 2 Ligante de Morte Celular Programada 1 , Receptor de Morte Celular Programada 1 , Regulação para Cima
12.
Immunol Cell Biol ; 88(7): 716-26, 2010 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-20212510

RESUMO

During a chronic infection such as tuberculosis, the pool of tissue dendritic cells (DC) must be renewed by recruitment of both circulating DC progenitors and monocytes (Mo). However, the microenvironment of the inflammatory site affects Mo differentiation. As DC are critical for initiating a Mycobacterium tuberculosis-specific T-cell response, we argue that interference of M. tuberculosis with a correct DC generation would signify a mechanism of immune evasion. In this study, we showed that early interaction of γ-irradiated M. tuberculosis with Mo subverts DC differentiation in vitro. We found that irradiated M. tuberculosis effect involves (1) the loss of a significant fraction of monocyte population and (2) an altered differentiation process of the surviving monocyte subpopulation. Moreover, in the absence of irradiated M. tuberculosis, DC consist in a major DC-specific intercellular adhesion molecule 3-grabbing non-integrin receptor (DC-SIGN(high))/CD86(low) and minor DC-SIGN(low)/CD86(high) subpopulations, whereas in the presence of bacteria, there is an enrichment of DC-SIGN(low)/CD86(high) population. Besides, this population enlarged by irradiated M. tuberculosis, which is characterized by a reduced CD1b expression, correlates with a reduced induction of specific T-lymphocyte proliferation. The loss of CD1molecules partially involves toll-like receptors (TLR-2)/p38 MAPK activation. Finally, several features of Mo, which have been differentiated into DC in the presence of irradiated M. tuberculosis, resemble the features of DC obtained from patients with active tuberculosis. In conclusion, we suggest that M. tuberculosis escapes from acquired immune response in tuberculosis may be caused by an altered differentiation into DC leading to a poor M. tuberculosis-specific T-cell response.


Assuntos
Células Dendríticas/imunologia , Células Dendríticas/microbiologia , Adulto , Antígenos CD1/metabolismo , Antígeno B7-2/metabolismo , Moléculas de Adesão Celular/metabolismo , Diferenciação Celular/imunologia , Proliferação de Células , Células Cultivadas , Humanos , Interleucina-10/metabolismo , Lectinas Tipo C/metabolismo , Teste de Cultura Mista de Linfócitos , Macrófagos/imunologia , Receptor de Manose , Lectinas de Ligação a Manose/metabolismo , Pessoa de Meia-Idade , Mycobacterium tuberculosis/patogenicidade , Receptores de Superfície Celular/metabolismo , Receptor 2 Toll-Like/metabolismo , Tuberculose/imunologia , Tuberculose/fisiopatologia , Proteínas Quinases p38 Ativadas por Mitógeno/metabolismo
13.
Hum Genet ; 127(1): 65-73, 2010 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-19771452

RESUMO

Tuberculosis (TB) is a global public health problem and a source of preventable deaths each year, with 8.8 million new cases of TB and 1.6 million deaths worldwide in 2005. Approximately, 10% of infected individuals develop pulmonary or extrapulmonary TB, suggesting that host defense factors influence development of active disease. Toll-like receptor' (TLR) polymorphisms have been associated with regulation of TLR expression and development of active TB. In the present study, 71 polymorphisms in TLR1, TLR2, TLR4, TLR6, and TLR9 were examined from 474 (295 cases and 179 controls) African-Americans, 381 (237 cases and 144 controls) Caucasians, and from 667 (321 cases and 346 controls) Africans from Guinea-Bissau for association with pulmonary TB using generalized estimating equations and logistic regression. Statistically significant associations were observed across populations at TLR9 and TLR2. The strongest evidence for association came at an insertion (I)/deletion (D) polymorphism (-196 to -174) in TLR2 that associated with TB in both Caucasians (II vs. ID&DD, OR = 0.41 [95% CI 0.24-0.68], p = 0.0007) and Africans (II vs. ID&DD, OR = 0.70 [95% CI 0.51-0.95], p = 0.023). Our findings in three independent population samples indicate that variations in TLR2 and TLR9 might play important roles in determining susceptibility to TB.


Assuntos
População Negra/genética , Negro ou Afro-Americano/genética , Receptor 2 Toll-Like/genética , Receptor Toll-Like 9/genética , Tuberculose Pulmonar/genética , População Branca/genética , Frequência do Gene , Predisposição Genética para Doença , Variação Genética , Genótipo , Guiné-Bissau , Humanos , Desequilíbrio de Ligação , Polimorfismo de Nucleotídeo Único , Tuberculose Pulmonar/etnologia , Estados Unidos
14.
Eur J Immunol ; 39(9): 2450-8, 2009 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-19714575

RESUMO

Tuberculous pleurisy, one of the most common manifestations of extrapulmonary tuberculosis, is characterized by a T-cell-mediated hypersensitivity reaction along with a Th1 immune profile. In this study, we investigated functional cross-talk among T and NK cells in human tuberculous pleurisy. We found that endogenously activated pleural fluid-derived NK cells express high ICAM-1 levels and induce T-cell activation ex vivo through ICAM-1. Besides, upon in vitro stimulation with monokines and PAMP, resting peripheral blood NK cells increased ICAM-1 expression leading to cellular activation and Th1 polarization of autologous T cells. Furthermore, these effects were abolished by anti-ICAM-1 Ab. Hence, NK cells may contribute to the adaptive immune response by a direct cell-contact-dependent mechanism in the context of Mycobacterium tuberculosis infection.


Assuntos
Molécula 1 de Adesão Intercelular/metabolismo , Células Matadoras Naturais/imunologia , Mycobacterium tuberculosis , Linfócitos T/imunologia , Tuberculose Pleural/imunologia , Adulto , Antígeno CD11a/imunologia , Antígeno CD56/imunologia , Comunicação Celular/imunologia , Cisteína/análogos & derivados , Cisteína/farmacologia , Humanos , Molécula 1 de Adesão Intercelular/efeitos dos fármacos , Molécula 1 de Adesão Intercelular/imunologia , Interleucina-12/farmacologia , Interleucina-15/farmacologia , Interleucina-18/farmacologia , Lipopolissacarídeos/farmacologia , Lipoproteínas/farmacologia , Pessoa de Meia-Idade , Fosfotransferases (Aceptor do Grupo Fosfato)
15.
Hum Genet ; 126(5): 643-53, 2009 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-19575238

RESUMO

Tuberculosis (TB) has substantial mortality worldwide with 5-10% of those exposed progressing to active TB disease. Studies in mice and humans indicate that the inducible nitric oxide synthase (iNOS) molecule plays an important role in immune response to TB. A mixed case-control association study of individuals with TB, relatives, or close contact controls was performed in 726 individuals (279 case and 166 control African-Americans; 198 case and 123 control Caucasians). Thirty-nine single nucleotide polymorphisms (SNPs) were selected from the NOS2A gene for single SNP, haplotype, and multilocus interaction analyses with other typed candidate genes using generalized estimating equations. In African-Americans, ten NOS2A SNPs were associated with TB. The strongest associations were observed at rs2274894 (odds ratio (OR) = 1.84, 95% confidence interval (CI) [1.23-2.77], p = 0.003) and rs7215373 (OR = 1.67, 95% CI [1.17-2.37], p = 0.004), both of which passed a false discovery rate correction for multiple comparisons (q* = 0.20). The strongest gene-gene interactions were observed between NOS2A rs2248814 and IFNGR1 rs1327474 (p = 0.0004) and NOS2A rs944722 and IFNGR1 rs1327474 (p = 0.0006). Three other SNPs in NOS2A interacted with TLR4 rs5030729 and five other NOS2A SNPs interacted with IFNGR1 rs1327474. No significant associations were observed in Caucasians. These results suggest that NOS2A variants may contribute to TB susceptibility, particularly in individuals of African descent, and may act synergistically with SNPs in TLR4 and IFNGR1.


Assuntos
População Negra/genética , Predisposição Genética para Doença , Óxido Nítrico Sintase Tipo II/genética , Polimorfismo de Nucleotídeo Único , Receptores de Interferon/genética , Receptor 4 Toll-Like/genética , Tuberculose Pulmonar/genética , Adolescente , Adulto , Estudos de Casos e Controles , Criança , Mapeamento Cromossômico , Éxons/genética , Família , Feminino , Genótipo , Humanos , Íntrons , Masculino , Modelos Genéticos , Regiões Promotoras Genéticas , Estados Unidos/epidemiologia , População Branca/genética
16.
Rev. am. med. respir ; 9(2): 61-99, jun. 2009.
Artigo em Espanhol | LILACS | ID: lil-535632

RESUMO

Capítulo 1: La TB constituye un grave problema de salud pública aún no resuelto y una enfermedad marcadora de pobreza: el 95% de los casos se registra en países en vías de desarrollo y un 98% de las muertes se observa también en esos países. En nuestro país, en el 2006 ha habido 11.068 casos de tuberculosis, lo que representa una tasa de 28,4 casos por cada 100.000 habitantes. La necesidad de un Programa de Control de TB (PCT) implica una política de salud que responda a una estrategia nacional descentralizada y horizontal, donde el Estado asuma su responsabilidad indelegable como controlador, regulador, dispensador, promotor y rehabilitador de la salud de la población. El primer objetivo de todo PCT es el diagnóstico precoz y un adecuado tratamiento de los casos de TB. La isoniacida continúa siendo la droga de elección, avalada por 50 años de experiencia. La vacuna conocida como BCG sólo se administra una única dosis al nacer ó hasta los seis años si el niño no tiene certificado de vacunación ni cicatriz. Capítulo 2: La tuberculosis en trabajadores de la salud constituye un grave problema de salud pública. Los factores de los que depende que un individuo se infecte son: la concentración de gotas infectantes en el aire, el número de recambio del volumen de aire en el ambiente y el tiempo de exposición. Para implementar un programa para la prevención y tratamiento de la TB se deben implementar medidas administrativas o de gestión, medidas de control ambiental y medidas de protección respiratoria personal. Las medidas administrativas incluyen asignación de responsabilidades para el control, evaluación y mantenimiento del programa, evaluación del riesgo y desarrollo del plan de control, identificación de los pacientes susceptibles de padecer tuberculosis, manejo del paciente hospitalizado, educación, entrenamiento y asesoramiento sobre tuberculosis a los integrantes del equipo de salud. Las medidas de control ambiental incluyen tecnologías para remover ...


Assuntos
Adolescente , Adulto , Criança , Pessoa de Meia-Idade , Vacina BCG , Mycobacterium tuberculosis , Tuberculose/diagnóstico , Tuberculose/epidemiologia , Tuberculose/prevenção & controle , Tuberculose/tratamento farmacológico , Tuberculose/terapia , Argentina , Antituberculosos/administração & dosagem , Antituberculosos/uso terapêutico , Consenso
18.
Rev. am. med. respir ; 9(2): 61-99, jun. 2009.
Artigo em Espanhol | BINACIS | ID: bin-124847

RESUMO

Capítulo 1: La TB constituye un grave problema de salud pública aún no resuelto y una enfermedad marcadora de pobreza: el 95% de los casos se registra en países en vías de desarrollo y un 98% de las muertes se observa también en esos países. En nuestro país, en el 2006 ha habido 11.068 casos de tuberculosis, lo que representa una tasa de 28,4 casos por cada 100.000 habitantes. La necesidad de un Programa de Control de TB (PCT) implica una política de salud que responda a una estrategia nacional descentralizada y horizontal, donde el Estado asuma su responsabilidad indelegable como controlador, regulador, dispensador, promotor y rehabilitador de la salud de la población. El primer objetivo de todo PCT es el diagnóstico precoz y un adecuado tratamiento de los casos de TB. La isoniacida continúa siendo la droga de elección, avalada por 50 años de experiencia. La vacuna conocida como BCG sólo se administra una única dosis al nacer ó hasta los seis años si el niño no tiene certificado de vacunación ni cicatriz. Capítulo 2: La tuberculosis en trabajadores de la salud constituye un grave problema de salud pública. Los factores de los que depende que un individuo se infecte son: la concentración de gotas infectantes en el aire, el número de recambio del volumen de aire en el ambiente y el tiempo de exposición. Para implementar un programa para la prevención y tratamiento de la TB se deben implementar medidas administrativas o de gestión, medidas de control ambiental y medidas de protección respiratoria personal. Las medidas administrativas incluyen asignación de responsabilidades para el control, evaluación y mantenimiento del programa, evaluación del riesgo y desarrollo del plan de control, identificación de los pacientes susceptibles de padecer tuberculosis, manejo del paciente hospitalizado, educación, entrenamiento y asesoramiento sobre tuberculosis a los integrantes del equipo de salud. Las medidas de control ambiental incluyen tecnologías para remover ... (AU)


Assuntos
Adolescente , Adulto , Criança , Pessoa de Meia-Idade , Idoso , Mycobacterium tuberculosis/efeitos dos fármacos , Tuberculose/diagnóstico , Tuberculose/tratamento farmacológico , Tuberculose/epidemiologia , Tuberculose/prevenção & controle , Tuberculose/terapia , Vacina BCG , Antituberculosos/administração & dosagem , Antituberculosos/uso terapêutico , Argentina , Consenso
20.
Am J Respir Crit Care Med ; 179(3): 247-53, 2009 Feb 01.
Artigo em Inglês | MEDLINE | ID: mdl-19011154

RESUMO

RATIONALE: Human secretory leukocyte protease inhibitor (SLPI) displays bactericidal activity against pathogens such as Escherichia coli and Streptococcus. Furthermore, it has been reported that murine SLPI shows potent antimycobacterial activity. OBJECTIVES: The aim of the present study was to investigate whether human recombinant SLPI not only kills mycobacteria but also acts as a pattern recognition receptor for the host immune system. METHODS: For the in vivo experiment, BALB/c mice were infected by intranasal instillation with Mycobacterium bovis BCG and viable BCG load in lung homogenates was later determined. For the in vitro experiments, SLPI was incubated overnight with a suspension of M. bovis BCG or the virulent strain Mycobacterium tuberculosis H37Rv, and the percentage survival as well as the binding of SLPI to mycobacteria was determined. Furthermore, bacteria phagocytosis was also determined by flow cytometry. MEASUREMENTS AND MAIN RESULTS: Intranasal SLPI treatment decreased the number of colony-forming units recovered from lung homogenates, indicating that SLPI interfered with M. bovis BCG infection. Moreover, SLPI decreased the viability of both M. bovis BCG and H37Rv. We demonstrated that SLPI attached to the surface of the mycobacteria by binding to pathogen-associated molecular pattern mannan-capped lipoarabinomannans and phosphatidylinositol mannoside. Furthermore, we found that in the sputum of patients with tuberculosis, mycobacteria were coated with endogenous SLPI. Finally, we showed that phagocytosis of SLPI-coated mycobacteria was faster than that of uncoated bacteria. CONCLUSIONS: The present results demonstrate for the first time that human SLPI kills mycobacteria and is a new pattern recognition receptor for them.


Assuntos
Mycobacterium tuberculosis/fisiologia , Inibidor Secretado de Peptidases Leucocitárias/metabolismo , Tuberculose Pulmonar/metabolismo , Animais , Modelos Animais de Doenças , Ensaio de Imunoadsorção Enzimática , Citometria de Fluxo , Humanos , Camundongos , Camundongos Endogâmicos BALB C , Fagocitose , Escarro/química , Escarro/microbiologia , Tuberculose Pulmonar/imunologia , Tuberculose Pulmonar/microbiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...